Sagent gets OK for antibacterial drug
SCHAUMBURG, Ill. — Sagent has received approval from the Food and Drug Administration for its antibacterial drug.
The drug maker said that the FDA approved polymyxin B for injection USP. Sagent said that polymyxin B sulfate is used to treat infections of the urinary tract, meninges and bloodstream caused by susceptible strains of Pseudomonas aeruginosa.
The drug was developed in partnership with Strides Arcolab. Under the collaboration, Strides develops and supplies injectable products that Sagent will market in the United States.
Shire files suit against Amneal, Sandoz over generic Vyvanse
DUBLIN — Shire has filed patent infringement suits against two generic drug makers relating to its attention deficit hyperactivity disorder treatment.
Shire said it has filed lawsuits in the U.S. District Court for the District of New Jersey against Amneal Pharmaceuticals and Sandoz. Amneal and Sandoz recently filed abbreviated new drug applications with the Food and Drug Administration to market generic Vyvanse (lisdexamfetamine), an ADHD drug.
Citing the Hatch-Waxman Act, Shire said that the FDA mustn’t approve the ANDAs for generic Vyvanse until the patents expire on Aug. 23, 2014, or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier.
Diplomat finds its patients are satisfied with pharmacy’s services
FLINT, Mich. — Just about everybody seems satisfied with Diplomat Specialty Pharmacy’s services, according to the company’s 2011 patient satisfaction survey.
Diplomat mailed the survey to 1,545 customers in May, of whom 463 responded. Of those respondents, 90% said Diplomat exceeded their expectations; 98% said it met their expectations; and 99% said they were satisfied overall with the specialty pharmacy provider.
Diplomat president and CEO Phil Hagerman said the results affirmed the provider’s patient-focused model.
“This type of customer-provided data reinforces the importance and value of our company approach, which includes direct outreach to patients to maintain our high adherence rates and our proprietary eNAV IT platform,” Hagerman said. “Equally important, the survey results reflect positive patient feedback at a time when Diplomat is on a major growth spurt, nearly 50% year over year.”